For some time I've been tracking work on extending healthy lives and longevity, both from a scientific as well as an investment perspective. I indicated that there are a number of biotech startups that start out seeking to extend lifespan, but as a survival mechanism, end up choosing a disease that is more common with age and seeking to address that.
Life extending drugs Metformin and Rapamycin
Previously I've highlighted two drugs, Metformin and Rapamycin, developed for specific diseases, which might also extend lifespan as a side effect. Here is an update.
Metformin
A good summary of the current status of Metformin has been published recently in Endocrine Today. This article describes the history of Metformin development, which has culminated in it being the recommended first-line drug for treating type 2 diabetes both in the US and worldwide. Because it is available as a generic and is cheap to manufacture, this drug could be used as a long term anti-aging drug (~$4 for 1 month supply).
Metformin has a number of positive health effects beyond its use in treating type 2 diabetes, including applications for treating some patients with obesity.
A six year placebo controlled study on 3000 elderly patients is underway to explore Metformin protection of age related disease occurrence. There are indications that Metformin may be protective against growth of cancer cells.
Of course prescribing Metformin as a life extending/quality of life drug is not an immediate prospect, although there have been some studies on a possible life extending action by Metformin.
The commercial prospects for this drug are limited as it is no longer patented and there seems to be limited opportunity to develop a proprietary formulation as it is easily administered as a daily tablet.
Since it is clear that Metformin doesn't work for everyone, perhaps the future for this kind of life extending drug might be to integrate its use into a wellness portfolio, with screening to see whether you are likely to benefit from the drug. This would mean packaging the drug in an informatics-based service business. Of course the benefits of Metformin need to be better clarified, but after that there needs to be a business model sorted out that doesn't rely on a patented position for the actual drug itself.
Management of patient data is now coming of age with cloud based electronic health records and data management with companies like Commvault (NASDAQ:CVLT). While these companies at present focus on integrating and making available a wide range of patient data, it is a logical step for these kinds of providers to assist health providers to mine and integrate data with a view to promoting wellness and reducing the cost of treatment after people get sick. In fact this approach is already emerging with companies like Nextgen Healthcare (a subsidiary of Quality Systems (NASDAQ:QSII)). Investors looking for future investments in the healthcare area might keep an eye out for how companies like Commvault, and Nextgen are positioning themselves.
It isn't surprising that Craig Venter, who transformed the human genome project, is interested in this space with his company Human Longevity Inc. However, it has been argued that Human Longevity Inc is more a personalised medicine company than a longevity science company. So Human Longevity operates in a similar space to Nextgen Healthcare, except that a core feature of Venter's company is sequencing and annotating individual human genome data.
Rapamycin
The Rapamycin story is different to Metformin as in the case of Rapamycin a number of big pharma companies have a patent position on variants of Rapamycin (Sirolimus). Novartis (NYSE:NVS) Everolimus and Pfizer (NYSE:PFE) Temsirolimus have been investigated for kidney cancer treatments, and also in combination with other drugs for exploring treatment of various cancers. Everolimus may also have fertility sparing attributes for women being treated with chemotherapeutic agents.
Abbott (NYSE:ABT) Zotarolimus and private company Elixir Medical Corp Novolimus (which is an active metabolite of Rapamycin (Sirolimus)) have been tested as a cardiac stent coating. Everolimus has also been used as a cardiac stent coating.
The above patented Rapamycin derivatives leave the way open for a more conventional drug development program for anti-aging and quality of life improvement. No doubt as part of consideration of Rapamycin derivatives for life extension applications, there are senior executives in big pharma trying to work out how this could play out.
Unlike the situation with Metformin where life extension possibilities are being identified through data mining of a large patient base who use Metformin, especially for Type 2 diabetes, in the case of Rapamycin, trials are being established to test low doses both in large animals (dogs) and humans to test more directly life extension and quality of life improvements.
Dog trials: The first phase of the Dog Aging Project has been completed; it involved a low dose of Rapamycin. There were 24 middle-aged dogs treated with placebo or Rapamycin in a trial in Seattle. The key findings, which will be published, were that there were no significant side effects of Rapamycin treatment and also that positive effects on heart function compared to controls were similar to results found after treating old mice. The trial involved a small number of animals and it produced limited, but encouraging results.
The second phase of the Dog Aging Project involves treating middle-aged dogs with low doses of Rapamycin (with a placebo control) for 3 -5 years to understand if Rapamycin does cause increased lifespan and a better elderly life. A number of age-related parameters will be assessed before, during and after the 3-5 year Rapamycin dosing period. Key parameters to be measured include cognitive function, heart function, immunity and cancer incidence. The geographical reach of the second phase trial will extend throughout the US and hopefully overseas. At the low doses used, no adverse effects of Rapamycin are expected.
Human trials: There are currently two human clinical trials assessing low doses of Rapamycin in progress.
One trial sponsored by The University of Texas Health Sciences Center at San Antonio and due for completion in June 2017, involves treating healthy (includes those with chronic disease whose disease is stable) aged volunteers aged 70-95 years with a daily dose of Rapamycin or placebo for 8 weeks. The primary endpoint involves scientific measurements of immune response and T-cell function. Secondary outcomes involve physical performance (grip strength, walking speed) and cognitive performance based on 3 different tests.
A second trial, sponsored by the Mayo Clinic, is a Phase 1 study that involves a small open label trial, which will be followed by a randomized trial involving exercise or exercise plus low dose of Rapamycin. Patients will be 60 years or older. It looks like this study was preceded by a pilot study measuring senescence markers and physical function in elderly patients undergoing cardiac rehabilitation. Rapamycin treatment showed some improvement of senescence markers and physical performance, but no improvement in frailty in the pilot study. The interesting point is that Rapamycin at a low dose unlikely to cause any adverse effects, is being taken seriously as a potential life extension/quality of life treatment. There are interesting developments in Rapamycin-like drugs that may have better potential as life extending drugs than Rapamycin itself.
The next developments here will be if big Pharma starts to do trials on their proprietary (patented) forms of Rapamycin.
Conclusion
As is often the case when new fields of medicine are opened up, the treatment, the drug pricing and the means of commercialisation are all unclear. It is a twist to contemplate taking a drug when you are well, but not without precedent as aspirin is often taken at low doses to prevent heart attack and stroke.
Here I've discussed two business models for old drugs that may have life extension/quality of life improvements. For Metformin I suggest that it could be incorporated in a wellness program. For Rapamycin a more traditional drug development route is possible. Watch this space.
Author's note: I am not a financial advisor. I look for innovation in biotech and try to understand how this may be monetized. If my commentary helps shape your perspective on biotech investment, please consider following me.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The rest is here:
Metformin And Rapamycin: Signs Of (Extended) Life? How To Monetize? - Seeking Alpha
- About Us - Life Extension - December 19th, 2016 [December 19th, 2016]
- Real Life Extension: Caloric Restriction or Intermittent ... - January 27th, 2017 [January 27th, 2017]
- Bruce Power invests millions in maintenance | The London Free Press - London Free Press - February 7th, 2017 [February 7th, 2017]
- Extension Spotlight: The importance of a good education | Life ... - NRToday.com - February 7th, 2017 [February 7th, 2017]
- From Confines Of Russia, Controversial Stem-Cell Surgeon Tries To Weather Scandal - RadioFreeEurope/RadioLiberty - February 7th, 2017 [February 7th, 2017]
- Volm Companies' Matt Alexander Talks Light-Blocker Half-N-Half Bags - And Now U Know - February 7th, 2017 [February 7th, 2017]
- Plymouth warship HMS Argyll sets sail again after 20-month refit - Plymouth Herald - February 7th, 2017 [February 7th, 2017]
- 'Orphan Black' Final Season Premiere Date Set at BBC America - Yahoo TV (blog) - February 7th, 2017 [February 7th, 2017]
- Radical Life Extension Is Already Here, But We're Doing it ... - February 7th, 2017 [February 7th, 2017]
- Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 - Vail Daily News - February 8th, 2017 [February 8th, 2017]
- ATS Automation Tooling Systems' (ATSAF) CEO Anthony Caputo on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha - February 8th, 2017 [February 8th, 2017]
- Weslaco ISD Students Re-Stripe Crosswalk to Promote School Zone Safety - RGVProud - February 8th, 2017 [February 8th, 2017]
- There is No Limit to Human Life Extension - Futurism - February 8th, 2017 [February 8th, 2017]
- Weaving the practice of self-compassion into your life - Michigan State University Extension - February 9th, 2017 [February 9th, 2017]
- Italian company competes for $16B US Air Force jet trainer contract - Dayton Daily News - February 9th, 2017 [February 9th, 2017]
- Human Life Could Be Extended Indefinitely, Study Suggests - EconoTimes - February 9th, 2017 [February 9th, 2017]
- DARPA hits snag in GEO satellite service plan - Network World - February 9th, 2017 [February 9th, 2017]
- My Mother is 100. She Does't Need Andrew Weil's 'Healthy Aging' You do - The Good Men Project - February 10th, 2017 [February 10th, 2017]
- Orbital ATK Sues DARPA Over Satellite-Repairing Robots | Inverse - Inverse - February 13th, 2017 [February 13th, 2017]
- Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate - PR Newswire (press release) - February 14th, 2017 [February 14th, 2017]
- SRS's Melter 2 to be replaced | News | northaugustastar.com - The Star - February 15th, 2017 [February 15th, 2017]
- The Next Pseudoscience Health Craze Is All About Genetics - Gizmodo - February 15th, 2017 [February 15th, 2017]
- These Serious Marathoners Lived 19 Years Longer Than Average - Runner's World - February 16th, 2017 [February 16th, 2017]
- Why Do People Want to Live So Long, Anyway? - TIME - February 16th, 2017 [February 16th, 2017]
- How Silicon Valley Is Trying to Hack Its Way Into a Longer Life - TIME - February 16th, 2017 [February 16th, 2017]
- Major South African coal extension project on cards South32 - Creamer Media's Mining Weekly - February 16th, 2017 [February 16th, 2017]
- When Screening for Disease, Risk is as Important to Consider as ... - University of Virginia - February 20th, 2017 [February 20th, 2017]
- John Killebrew: Honoring a life of service - Delta Farm Press - February 20th, 2017 [February 20th, 2017]
- No limit to how long we could extend our lives, say researchers - EWN - Eyewitness News - February 20th, 2017 [February 20th, 2017]
- Extension: Taking care of the rocks in your life - Lifestyle - The ... - Carthage Press - February 21st, 2017 [February 21st, 2017]
- Long life expectancy for Leopard [IDEX17D3] - IHS Jane's 360 - February 21st, 2017 [February 21st, 2017]
- A UO lab digs into worms in the quest to lengthen human life - AroundtheO - February 22nd, 2017 [February 22nd, 2017]
- L3 MAPPS to Supply Digital Control Computer System Hardware for Bruce Unit 6, Supporting Life Extension and ... - Nuclear Street - Nuclear Power Plant... - February 22nd, 2017 [February 22nd, 2017]
- Kambalda faces future with no nickel output - The West Australian - February 23rd, 2017 [February 23rd, 2017]
- L3 MAPPS to Supply Digital Control Computer System Hardware for ... - Nuclear Street - Nuclear Power Plant News, Jobs, and Careers (press release)... - February 23rd, 2017 [February 23rd, 2017]
- This Company With Anti-Aging Drug Is Secretly Preparing For Trump's New FDA - Forbes - February 24th, 2017 [February 24th, 2017]
- Weather Radar in Amarillo Gets Upgrade - Guymondailyherald - February 24th, 2017 [February 24th, 2017]
- PACKAGING INNOVATIONS 2017: Anti-microbial absorbent pads ... - WorldPressOnline (press release) - February 24th, 2017 [February 24th, 2017]
- A business case for wind farm lifetime extension - Windpower Engineering (press release) - February 24th, 2017 [February 24th, 2017]
- Mount Tam With Anti-Aging Drug Is Secretly Preparing For Trump's New FDA - ValueWalk - March 1st, 2017 [March 1st, 2017]
- Derek Carr passionate about Silver and Black: 'I'm a Raider for life' - The Mercury News - March 1st, 2017 [March 1st, 2017]
- Bruce Power Life Extension Project On Top - Bayshore Broadcasting News Centre - March 1st, 2017 [March 1st, 2017]
- Derek Carr on Contract Extension: I'm a Raider for life - Just Blog Baby (blog) - March 2nd, 2017 [March 2nd, 2017]
- How this Baltimore company is using AI to make supplements smarter - Technical.ly Brooklyn - March 3rd, 2017 [March 3rd, 2017]
- Rio cut takes the shine off Argyle - The West Australian - March 4th, 2017 [March 4th, 2017]
- Bruce Power Life-Extension Program ranked top infrastructure project of 2017 - southwesternontario.ca - March 8th, 2017 [March 8th, 2017]
- Il-76 flown beyond service life before fatal engine explosion - Flightglobal - March 11th, 2017 [March 11th, 2017]
- Your Questions About Silicon Valley's Quest to Live Forever, Answered - The New Yorker - April 8th, 2017 [April 8th, 2017]
- Cormorant, Griffon upgrade projects get new lift - Skies Magazine (press release) - June 6th, 2017 [June 6th, 2017]
- Garoppolo wants to play, open to extension - ESPN - June 6th, 2017 [June 6th, 2017]
- Refixia (nonacog beta pegol; N9-GP) approved - GlobeNewswire (press release) - June 6th, 2017 [June 6th, 2017]
- New life breathed into decades-old dream of a Cavendish extension ... - Montreal Gazette - June 6th, 2017 [June 6th, 2017]
- Some JSTARS aircraft could fly into 2034 - Flightglobal - June 7th, 2017 [June 7th, 2017]
- Cormorant, Griffon upgrade projects get new lift - Vertical Magazine (press release) - June 7th, 2017 [June 7th, 2017]
- The Ugly: Post #3 on the NNSA's FY2018 Budget Request - All Things Nuclear - June 7th, 2017 [June 7th, 2017]
- Kincardine Company To Add Jobs To Support Bruce Power - BlackburnNews.com - June 8th, 2017 [June 8th, 2017]
- Latin American sisters in US 'build bridges' during 'challenging time' - Catholic News Service - June 8th, 2017 [June 8th, 2017]
- Modernizing Nuclear Deterrents No. 1 Priority, DoD Officials Tell ... - Department of Defense - June 8th, 2017 [June 8th, 2017]
- EXTENSION CORNER: It's crucial for producers to know how to manage weeds - Gadsden Times - June 9th, 2017 [June 9th, 2017]
- Robot Bina48 Makes a Guest Appearance at 'Stitch and Bitch' - Seven Days - June 10th, 2017 [June 10th, 2017]
- Patriots WR Julian Edelman's father would love his son to be "a Patriot for life" - Pats Pulpit - June 11th, 2017 [June 11th, 2017]
- Orphan Black: 3 Major Revelations From the Season 5 Premiere - TV Guide (blog) - June 11th, 2017 [June 11th, 2017]
- GARDENING: Harvest tomatoes before the birds do - Odessa American - June 11th, 2017 [June 11th, 2017]
- 'Orphan Black' Season 5 Premiere Recap: Life is Tough on and off the Island - BuddyTV (blog) - June 12th, 2017 [June 12th, 2017]
- Griffon helicopter replacement not in the cards for the Liberals anytime soon - Ottawa Citizen - June 12th, 2017 [June 12th, 2017]
- DFI Marketing uses new post-harvest technology with melon exports - The Packer - June 13th, 2017 [June 13th, 2017]
- Elio Motors Given An Extension To Bring Its Three-Wheeled Vehicle ... - Jalopnik - June 13th, 2017 [June 13th, 2017]
- Rec tax extension moves closer to November ballot - West Life News - June 14th, 2017 [June 14th, 2017]
- Bioverativ announces FDA acceptance of Investigational New Drug ... - EconoTimes - June 14th, 2017 [June 14th, 2017]
- Charlie Gard: European Court orders life support extension - BBC News - June 14th, 2017 [June 14th, 2017]
- Extension Spotlight: Are you ready to preserve the harvest? | Life ... - NRToday.com - June 14th, 2017 [June 14th, 2017]
- The Case of the Missing Numbers - All Things Nuclear - June 16th, 2017 [June 16th, 2017]
- Hacking the human lifespan / Boing Boing - Boing Boing - June 17th, 2017 [June 17th, 2017]
- CNO Richardson: Perry Frigates Only Inactive Hulls Navy Considering Returning to Active Fleet; DDG Life Extension ... - USNI News - June 17th, 2017 [June 17th, 2017]
- USAF seeks to expand F-16 life-extension program - Quwa - Quwa Defence News & Analysis Group - June 20th, 2017 [June 20th, 2017]
- Baker proposes $500M life sciences extension - Worcester Business Journal - June 20th, 2017 [June 20th, 2017]
- Life Extension News | March 2017 Issue | Life Enhancement ... - June 21st, 2017 [June 21st, 2017]
- Pop-culture-palooza - Mountain View Voice - June 21st, 2017 [June 21st, 2017]
- Kids experience a day in the life of a scientist - Scottsbluff Star Herald - June 23rd, 2017 [June 23rd, 2017]
- A First For Jazz Technical Services - MRO Network - June 23rd, 2017 [June 23rd, 2017]